Kairos Pharma, Ltd.
KAPA · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $23,641 | $12,204 | $14,859 | $20,880 |
| - Cash | $5,575 | $3,034 | $3,616 | $1,272 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $18,066 | $9,170 | $11,243 | $19,608 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$40 | -$40 | -$40 | -$40 |
| % Margin | – | – | – | – |
| EBITDA | -$1,358 | -$1,382 | -$1,222 | -$807 |
| % Margin | – | – | – | – |
| Net Income | -$1,398 | -$1,422 | -$1,262 | -$980 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.07 | -0.083 | -0.08 | -0.071 |
| % Growth | 15.3% | -3.9% | -11.5% | – |
| Operating Cash Flow | -$838 | -$805 | -$714 | -$1,803 |
| Capital Expenditures | $838 | $0 | $0 | $0 |
| Free Cash Flow | $0 | -$805 | -$714 | -$1,803 |